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Background: Gender disparity, with respect to women receiving less medical therapy, un-
dergoing fewer invasive procedures, and experiencing worse outcome than men, has been
noted in various observational and randomized trials, though guidelines on acute coronary
syndrome (ACS) are gender-neutral. Indian data with focus on women with ACS are lacking.
Aim: This study was undertaken to give us an insight on the clinical presentation, risk
factors, and in-hospital outcome of ACS in women and at 30 days.
Materials and methods: 133 successive cases of women presenting with ACS, who met the
inclusion criteria between 2012 and 2014, were included. Cases were grouped into ST
elevation myocardial infarction (STEMI), non ST elevation myocardial infarction (NSTEMI),
and unstable angina (UA).
Results and conclusion: The mean age was 64.4  11 years. The mean BMI was 23.64  3.23 kg/
m2. Diabetes was present in 58.3% in NSTEMI, 65.1% in STEMI, and 57.1% in UA group.
Hypertension was found in 75% of NSTEMI, 60.2% of STEMI, and 71.4% of UA group. Severe
MR was found in 11.1% of NSTEMI and 3.6% of STEMI patients. 8.3% of NSTEMI and 15.7% of
STEMI patients presented in Killips class IV. Single vessel disease was most commonly found
across the spectrum of ACS. 68.7% patients in STEMI group underwent primary angioplasty.
5.6% of NSTEMI and 7.2% in STEMI group had contrast-induced nephropathy (CIN). All
deaths were noted in STEMI group with eight in-hospital deaths and three during 30-day
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follow-up period. Killips class III and IV and higher grace score (>150) were predictors of in-
hospital mortality. Chronic kidney disease, ischemic mitral regurgitation, LV clot, and in-
hospital cardiac arrest were associated with higher risk.
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Cardiovascular disease has emerged as a major health burden
in developing countries. Signiﬁcant differences in the preva-
lence of coronary artery disease (CAD) exist with respect to
gender, age, and ethnicity. It is predicted that more than half
the worldwide cardiovascular disease risk burden will be borne
by the Indian subcontinent in the next decade, according to a
recent epidemiological study.1 In 2003, the prevalence of CAD
in India was estimated to be 3–4% in rural areas and 8–10% in
urban areas (six-fold higher compared with 40 years ago). At
any given age, the prevalence of CAD is greater in men than in
women. Nonetheless, many recent reports concluded that
women with CAD have a worse prognosis than men with this
disease. The type of ischemic event shows gender-speciﬁc
differences. Most clinical trials have enrolled primarily men,
and the results have generally been extrapolated to women.
A randomized substudy of the OASIS 5 trial (Organization to
Assess Strategies in Acute Ischemic Syndromes) and an
accompanying meta-analysis of prior studies of percutaneous
coronary intervention (PCI) in women presenting with an
acute coronary syndrome (ACS) suggest that women do worse
with an early invasive strategy. They have been reported to
undergo cardiac catheterization and consequently revascular-
ization procedures less often than men.2 There have been
conﬂicting results when analyzed by gender in randomized
and registry studies of primary PCI for ST elevation myocardial
infarction (STEMI). Although large trials including women's
health initiative and the women's ischemia syndrome
evaluation have shed light on clinical characteristics, diagno-
sis, and outcome in women, they are largely western studies.
In a study undertaken in Kerala at a tertiary center, women
with STEMI had higher mortality rates than males with
STEMI.3 In Kerala ACS registry,4 the largest ACS data till date in
the Indian scenario involving 25,748 patients over 2 years and
across 125 centers had 22.6% women, and CREATE registry5
showed that 23.6% of ACS were women.
2. Materials and methods
This was an observational study with 30-day follow-up,
conducted at Fortis Hospital, Cunningham Road, Bangalore. It
aimed to provide information on the risk factors and
treatment outcome in natural settings. The subjects were
female patients, who were presenting for the ﬁrst time with a
diagnosis of ACS, at our hospital. Once the patients met the
inclusion and exclusion criteria as deﬁned, they were enrolled
in the study after signing the informed consent. Women
whose age is greater than 18 years and diagnosed with ACSwere included. Age less than 18 years, prior heart failure, prior
ischemic heart disease, and those unwilling to participate in
the study or sign the informed consent were excluded. STEMI,
non ST elevation myocardial infarction (NSTEMI), and
unstable angina (UA) were diagnosed following current
guidelines.
Data collection was done in two phases – in hospital and 30-
day telephonic follow-up. The in-hospital survey was per-
formed when the patient presented with ACS for the ﬁrst time.
The postdischarge survey was done at 30 days. The data were
collected from the patients and recorded in a prepared Case
Report Form (CRF). Demographic details, medical history,
information on diet, substance use, and hospitalization details
were collected.
2.1. Statistical analysis
Analysis of data was done using Statistical Package for Social
Sciences (SPSS) software version 15. The descriptive results are
displayed as subgroups of STEMI, NSTEMI, and UA. All the
numerical data are presented as mean  standard deviations.
All the categorical data are presented as frequency and
percentages. The results are presented in tables and graphs.
Multivariate logistic regression analysis was done to assess the
odds of variables affecting the in-hospital mortality.
3. Results
133 subjects were enrolled into the study after meeting the
inclusion criteria. The recruitment period was from May 2011
to December 2013. The subjects were followed up for a period
of 30 days. There were 11 patients who died during the study
period. Most patients belonged to 61–70 years stratiﬁed age
group across all ACS subtypes. The mean age was 64.4  11
years. The mean BMI was 23.64  3.23 kg/m2.
16.7% presented within 4 h after symptom onset and 58.3%
presented more than 12 h after symptom onset in the NSTEMI
group; 18.1% patients in STEMI group presented within 4 h of
symptom onset and 38.6% after 12 h. 64.3% patients in UA
group presented 12 h after symptom onset.
Most patients presented with typical chest discomfort in all
3 subgroups. 1 patient in NSTEMI and 6 patients in STEMI
group presented with syncope.
38.9% in NSTEMI, 36.1% in STEMI, and 21.4% in UA group
received premeditation with antiplatelets before reaching the
hospital. 6% in STEMI group received thrombolysis at the point
of ﬁrst medical contact.
Echocardiography revealed moderate mitral regurgitation
(MR) in 5.6% of NSTEMI and 6% of STEMI patients. Severe MR
was found in 11.1% of NSTEMI and 3.6% of STEMI patients.
Fig. 1 – Distribution of LV systolic dysfunction in terms of EF
in ACS subgroups.
Table 2 – In-hospital complications.
Number (%)
NSTEMI STEMI UA
Overall complications 10 (27.8%) 23 (27.7%) 1 (7.1%)
Local hematoma None 2 (2.4%) None
Bleeding None 2 (2.4%) None
Contrast-induced
nephropathy
2 (5.6%) 6 (7.2%) None
Ischemic MR 3 (8.3%) 6 (7.2%) None
Septal rupture None None None
Free wall rupture None None None
Left ventricle aneurysm 1 (2.8%) 1 (1.2%) None
Left ventricle clot None 3 (3.6%) None
Cardiac arrest 2 (5.6%) 3 (3.6%) None
Hypoxic ischemic
encephalopathy
None 2 (2.4%) None
Cardiac tamponade 1 (2.8%) None None
Pericarditis 1 (2.8%) 2 (2.4%) None
Raised liver enzymes None 1 (1.2%) None
Sepsis 6 (16.7%) None 1 (7.1%)
TIA/CVA None None None
In-hospital death 0 8 (9.6%) None
Table 1 – Risk factor profile.
Number (%)
NSTEMI STEMI UA
DM 21 (58.3%) 54 (65.1%) 8 (57.1%)
Hypertension 27 (75%) 50 (60.2%) 10 (71.4%)
Hypothyroidism 5 (13.9%) 14 (16.9%) 1 (7.1%)
CKD 1 (2.8%) 7 (8.4%) 2 (14.3%)
COPD 1 (2.8%) 6 (7.2%) 0
Anemia 1 (2.8%) 8 (9.6%) 0
Smoking 0 1 (1.2%) 0
Tobacco 0 2 (2.4%) 0
Family history of CAD 20 (55.6%) 43 (51.8%) 3 (21.4%)
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Table 1 depicts the risk factor proﬁle.
Troponin positivity was documented in all patients with
NSTEMI and in 75.9% of STEMI patients. Troponin T in our
study was done at admission; serial values have not been
considered in the present study. Fig. 2 depicts the distribution
of MI type in STEMI.
10.8% received thrombolysis in STEMI group. 115 patients
underwent CAG, 80.6% in NSTEMI group, 90.4% in STEMI group,
and 78.6% in UA group. Single vessel disease was most
commonly found across the spectrum of ACS. 13.9% in
NSTEMI, 10.8% in STEMI, and 14.3% in UA group had TVD.
Left main involvement was seen in 3 patients each of STEMI
and NSTEMI group. Of the patients who underwent PCI
procedure, 39.2% had radial access approach and 60.8% via
femoral approach.
69.4% in NSTEMI group underwent PCI; 7 patients of
posterior wall MI underwent primary angioplasties. 68.7%
(POBA+ PAMI) patients in STEMI group underwent primary
angioplasty; 42.9% patients in UA group underwent PCI. Use of
manual thrombus aspiration using export/thrombuster device
was done in 8.3% of NSTEMI and 33.7% patients in STEMI
group. Multivessel PCI was done in 8.3% NSTEMI and 6% STEMI
patients and none in UA group. Staged PCI was done in 3.6% ofFig. 2 – Distribution of MI type in STEMI.STEMI patients. IABP was used in 3.6% of STEMI patients and
TPI was used in 9.6% patients. 9 (6.77%) patients were put on
assisted ventilation and all were in STEMI subgroup. GPIIb/IIIa
inhibitors were used in 57.14% patients of ACS. Tiroﬁban was
used in 61.1% in NSTEMI and 60.2% in STEMI.
All patients received aspirin across all ACS groups;
Ticagrelor use was 11.1% in NSTEMI, 8.4% in STEMI, and
21.4% in UA group. 42.2% of STEMI patients received Prasugrel
and 30.6% in NSTEMI group. Clopidogrel was used in 94.4%
NSTEMI and 94% of STEMI patients; 39.9% of patients had a
switch over. All patients initially received statins, and in 1
patient, it was later discontinued because of raised liver
enzymes. 92.9% of UA, 77.1% in STEMI, and 75% in NSTEMI
received beta-blockers. Use of angiotensin converting enzyme
inhibitors was 83.3% in NSTEMI and 78.3% in STEMI group.
Table 2 depicts in-hospital complications.
7 patients in STEMI (six of IWMI and one AWMI) group and 1
in NSTEMI had complete heart block. 4 patients in STEMI (three
IWMI and one AWMI) and 1 in NSTEMI had VT/VF. All deaths
were noted in STEMI group, with eight in-hospital deaths and
three during 30-day follow-up period. 3 patients who died had
atypical clinical presentation.
In-hospital mortality was noted to increase with increasing
age in regression analysis. Chronic kidney disease (CKD) was
found to increase the risk. On multivariate regression analysis,
breathlessness and syncope were associated with increased
risk. Tachycardia and hypotension increased the odds.
Hypotension, Killips class III and IV and higher grace score
(>150), and moderate and severe LV dysfunction were
predictors of in-hospital mortality. Table 3 depicts risk
estimate for in-hospital death.
4. Discussion
Gender disparity in cardiac diagnosis and treatment has been
investigated thoroughly since Ayanian2 ﬁrst described this
Table 3 – Risk estimate for in-hospital death.
OR 95%
conﬁdence
interval
Value Upper Lower
Variables
Age group 51–60 (years) (Yes/No) 0.359 0.043 2.986
Age group 61–70 (years) (Yes/No) 1.267 0.324 4.953
Age group 71–80 (years) (Yes/No) 1.579 0.305 8.186
Age group >80 (years) (Yes/No) 4.143 0.737 23.300
Diabetes mellitus (Yes/No) 1.221 0.291 5.115
Hypertension (Yes/No) 1.925 0.383 9.669
Chronic kidney disease (Yes/No) 8.357 1.718 40.650
COPD/bronchial asthma (Yes/No) 2.458 0.263 22.973
Anemia (Yes/No) 1.813 0.201 16.339
Family history CAD (Yes/No) 0.113 0.014 0.934
Clinical variables
Complete heart block (Yes/No) 2.089 0.228 19.128
Ventricular tachycardia/ventricular
ﬁbrillation (Yes/No)
3.750 0.374 37.599
Systolic blood pressure ≤90 (Yes/No) 6.286 1.508 26.202
Systolic blood pressure >90 (Yes/No) 0.159 0.038 0.663
Killips Class III (Yes/No) 5.813 1.403 24.081
Killips Class IV (Yes/No) 11.667 2.755 49.404
Grace score group 100–49 (Yes/No) 0.243 0.049 1.217
Grace score group 150–199 (Yes/No) 6.131 1.518 24.764
Grace score group 200–249 (Yes/No) 11.524 1.648 80.567
Left main coronary artery (Yes/No) 2.975 0.309 28.602
Temporary pacemaker
implantation (Yes/No)
5.619 0.955 33.076
Thrombus aspiration (Yes/No) 2.207 0.296 16.446
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risk factors in women, an underemphasized study group.
Majority of patients in our study belonged to the age strata
of 61–70 years across all ACS subtypes. 7.5% patients were
more than 80 years. Older the age, higher was the odds of in-
hospital mortality. A majority of women in our study were
postmenopausal (90.2%), which reinforces the observation by
Rissam et al.6 that postmenopausal females need special
attention as they constitute a distinct subgroup at a high risk
for CAD.
Most patients presented with typical chest discomfort in all
3 subgroups (69.4% in NSTEMI, 72.3% in STEMI, and 71.4% in UA
group). 1 patient in NSTEMI and 6 patients in STEMI groupTable 4 – Comparison of acute coronary syndromes in developed
both men and women and involve a large sample.
STEMI NSTEMI Mean
age (years)
Time t
admis
thrombo
Our study 62.4% 27.1% 64.4 (SD 11) 42
CREATE 61% 39% 57 50
Global registry
of ACS
30–40% 60–70% 64–69 
European heart
surveys
42% 51% 63 40
US National
registry of MI
– – 68 32presented with syncope. In a study by Canto et al.,7 42% of
women presented without typical chest discomfort, and
gender-speciﬁc differences in MI presentation without chest
discomfort became progressively smaller with advancing age.
The in-hospital mortality rate was 14.6% for women and 10.3%
for men. Younger women presenting without chest pain had
greater hospital mortality than younger men without chest
pain, and these sex differences decreased or even reversed
with advancing age, with adjusted OR for 65–74 years, 0.91 (95%
CI, 0.88–0.95), and 75 years or older, 0.81. All 3 patients who
died and who had atypical clinical presentation had age more
than 65 years in our study, which is concordant with the data.
The percentage of subjects with diabetes mellitus (58.3% in
NSTEMI, 65.1% in STEMI, and 57.1% in UA) was much higher
than in both CREATE registry5 (30.4%) and the INTERHEART
study (30.2%).8 The mean glycosylated hemoglobin % was
found to be 7.24  2.03, suggesting that majority of diabetics
had uncontrolled diabetes. The percentage of hypertensives
(75% of NSTEMI, 60.2% of STEMI, and 71.4% of UA) was also high
when compared to the CREATE registry (37.7%)5 and the
INTERHEART study (29.6%). This difference in prevalence of
the major risk factors is probably due to regional differences, in
the Indian population. Compared with men, women were
signiﬁcantly older and had higher prevalence of hypertension
and hyperlipidemia in HORIZON-AMI9 subgroup analysis.
25% of NSTEMI and 12% of STEMI presented in Killips class
III. 8.3% of NSTEMI and 15.7% of STEMI patients presented in
Killips class IV. 21.7% in Kerala ACS had Killips class >1; 38.6%
women had Killips class II–IV in SWEDEHEART study.10
The mean total cholesterol level was higher in our study
(184.4  39.46 mg/dl) than that found among MI cases in
Tirupati, India (177.07  8.49).11 The same was noticed for
mean LDL level also (121.6  51.4 mg/dl). However, the levels of
the protective HDL were also found to be lower in our study
(35.2  7.69 mg/dl) than in the earlier study (46  1.55 mg/dl).11
The lipid abnormalities were present in 61.5% in the INTER-
HEART8 study and in 38.75% in a study by Bhasin et al.
(38.75%).11 It suggests high prevalence of dyslipidemia in the
general population.
Of the patients who underwent CAG, 66% received
revascularization in their study in comparison to 83.6% in
our study. The higher cumulative percentage is probably
related to the fact that ours is a tertiary cardiac care hospital.
PCI was done in only 11.9% of patients in Kerala ACS registry and developing countries; the registry data are inclusive of
aken for
sion to
lysis (min)
PAMI STEMI – 30-day
mortality
NSTEMI – 30-day
mortality
.5 68.7% 13.2% 0
 8% 9% 4%
– 40% 8% 3%
 40% 7% 1%
–38 36% 8% –
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by Sadowski et al.12 12% of STEMI patients received thrombol-
ysis.
68.7% patients underwent primary angioplasty in our
study. 82.8% received thrombolysis in a study at CMC Vellore13
involving 1320 patients where women constituted 16.2%. In a
study by Mady Moriel et al.,14 in STEMI-patients, acute
reperfusion was less frequent in women than in men (53%
vs. 63%, respectively, p = 0.01; nonsigniﬁcant after age adjust-
ment); reperfusion by thrombolysis was done in 30% patients
and PAMI in 70% of STEMI. In CADILLAC trial,15 female gender
was an independent predictor of MACE and bleeding compli-
cations, although co-morbid risk factors and body surface area,
and not gender, predicted 1-year death. For women, primary
stenting resulted in a reduction in 1-year MACE from 28.1% to
19.1%. Table 4 gives the comparison of registry data.
11 deaths (8.3%) were noted; 8 (6%) in hospital and 3 (2.3%)
in the follow-up period. All of them belonged to STEMI group.
3.9% in Kerala ACS registry had in-hospital mortality with 8.2%
in STEMI group. The registry data encompass both men and
women. In AMI-FLORENCE registry the in-hospital mortality
for women was 16%.
More research with focus on treatment strategies, including
invasive strategies, needs to be addressed.
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